Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.00
SURG's Cash to Debt is ranked higher than
55% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. SURG: 4.00 )
Ranked among companies with meaningful Cash to Debt only.
SURG' s 10-Year Cash to Debt Range
Min: 0.01  Med: 10000.00 Max: No Debt
Current: 4
Equity to Asset 0.70
SURG's Equity to Asset is ranked higher than
59% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. SURG: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
SURG' s 10-Year Equity to Asset Range
Min: 0.57  Med: 0.87 Max: 0.98
Current: 0.7
0.57
0.98
Interest Coverage 241.11
SURG's Interest Coverage is ranked lower than
58% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. SURG: 241.11 )
Ranked among companies with meaningful Interest Coverage only.
SURG' s 10-Year Interest Coverage Range
Min: 1.56  Med: 10000.00 Max: 9999.99
Current: 241.11
1.56
9999.99
F-Score: 5
Z-Score: 4.37
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.69
SURG's Operating margin (%) is ranked higher than
68% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. SURG: 8.69 )
Ranked among companies with meaningful Operating margin (%) only.
SURG' s 10-Year Operating margin (%) Range
Min: -8.11  Med: 6.50 Max: 15
Current: 8.69
-8.11
15
Net-margin (%) 6.04
SURG's Net-margin (%) is ranked higher than
64% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. SURG: 6.04 )
Ranked among companies with meaningful Net-margin (%) only.
SURG' s 10-Year Net-margin (%) Range
Min: -7.41  Med: 4.08 Max: 11.01
Current: 6.04
-7.41
11.01
ROE (%) 6.74
SURG's ROE (%) is ranked higher than
59% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. SURG: 6.74 )
Ranked among companies with meaningful ROE (%) only.
SURG' s 10-Year ROE (%) Range
Min: -2.53  Med: 4.66 Max: 16.86
Current: 6.74
-2.53
16.86
ROA (%) 4.95
SURG's ROA (%) is ranked higher than
66% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. SURG: 4.95 )
Ranked among companies with meaningful ROA (%) only.
SURG' s 10-Year ROA (%) Range
Min: -2.44  Med: 3.42 Max: 11.03
Current: 4.95
-2.44
11.03
ROC (Joel Greenblatt) (%) 18.47
SURG's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. SURG: 18.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SURG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13.95  Med: 13.46 Max: 40.77
Current: 18.47
-13.95
40.77
Revenue Growth (3Y)(%) 4.70
SURG's Revenue Growth (3Y)(%) is ranked higher than
58% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. SURG: 4.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SURG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.6  Med: 5.10 Max: 50.6
Current: 4.7
-2.6
50.6
EBITDA Growth (3Y)(%) -13.40
SURG's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. SURG: -13.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SURG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 10.10 Max: 115.4
Current: -13.4
0
115.4
EPS Growth (3Y)(%) -19.50
SURG's EPS Growth (3Y)(%) is ranked lower than
72% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. SURG: -19.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SURG' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -9.75 Max: 122.4
Current: -19.5
0
122.4
» SURG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SURG Guru Trades in Q3 2014

Jim Simons 153,400 sh (+92.96%)
Chuck Royce 1,531,149 sh (unchged)
» More
Q4 2014

SURG Guru Trades in Q4 2014

Jim Simons 211,600 sh (+37.94%)
Chuck Royce 1,166,874 sh (-23.79%)
» More
Q1 2015

SURG Guru Trades in Q1 2015

Jim Simons 387,560 sh (+83.16%)
Chuck Royce 969,274 sh (-16.93%)
» More
Q2 2015

SURG Guru Trades in Q2 2015

Jim Simons 480,436 sh (+23.96%)
Chuck Royce 895,674 sh (-7.59%)
» More
» Details

Insider Trades

Latest Guru Trades with SURG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 37.28
SURG's P/E(ttm) is ranked higher than
56% of the 156 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. SURG: 37.28 )
Ranked among companies with meaningful P/E(ttm) only.
SURG' s 10-Year P/E(ttm) Range
Min: 5.03  Med: 27.51 Max: 335.63
Current: 37.28
5.03
335.63
Forward P/E 18.69
SURG's Forward P/E is ranked higher than
59% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 23.31 vs. SURG: 18.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.20
SURG's PE(NRI) is ranked higher than
57% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.40 vs. SURG: 24.20 )
Ranked among companies with meaningful PE(NRI) only.
SURG' s 10-Year PE(NRI) Range
Min: 5  Med: 26.55 Max: 335.63
Current: 24.2
5
335.63
P/B 2.53
SURG's P/B is ranked higher than
73% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. SURG: 2.53 )
Ranked among companies with meaningful P/B only.
SURG' s 10-Year P/B Range
Min: 0.49  Med: 2.00 Max: 9.59
Current: 2.53
0.49
9.59
P/S 2.31
SURG's P/S is ranked higher than
68% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. SURG: 2.31 )
Ranked among companies with meaningful P/S only.
SURG' s 10-Year P/S Range
Min: 0.34  Med: 1.77 Max: 7.18
Current: 2.31
0.34
7.18
PFCF 16.85
SURG's PFCF is ranked higher than
89% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 33.52 vs. SURG: 16.85 )
Ranked among companies with meaningful PFCF only.
SURG' s 10-Year PFCF Range
Min: 1.6  Med: 16.83 Max: 99999999.99
Current: 16.85
1.6
99999999.99
POCF 14.98
SURG's POCF is ranked higher than
86% of the 157 Companies
in the Global Medical Devices industry.

( Industry Median: 22.08 vs. SURG: 14.98 )
Ranked among companies with meaningful POCF only.
SURG' s 10-Year POCF Range
Min: 1.54  Med: 19.36 Max: 99999999.99
Current: 14.98
1.54
99999999.99
EV-to-EBIT 25.49
SURG's EV-to-EBIT is ranked higher than
65% of the 159 Companies
in the Global Medical Devices industry.

( Industry Median: 21.34 vs. SURG: 25.49 )
Ranked among companies with meaningful EV-to-EBIT only.
SURG' s 10-Year EV-to-EBIT Range
Min: -796.9  Med: 16.50 Max: 153.4
Current: 25.49
-796.9
153.4
Shiller P/E 36.29
SURG's Shiller P/E is ranked higher than
62% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 32.28 vs. SURG: 36.29 )
Ranked among companies with meaningful Shiller P/E only.
SURG' s 10-Year Shiller P/E Range
Min: 7.5  Med: 27.59 Max: 255
Current: 36.29
7.5
255
Current Ratio 4.08
SURG's Current Ratio is ranked higher than
69% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. SURG: 4.08 )
Ranked among companies with meaningful Current Ratio only.
SURG' s 10-Year Current Ratio Range
Min: 1.73  Med: 7.47 Max: 30
Current: 4.08
1.73
30
Quick Ratio 2.55
SURG's Quick Ratio is ranked higher than
60% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. SURG: 2.55 )
Ranked among companies with meaningful Quick Ratio only.
SURG' s 10-Year Quick Ratio Range
Min: 0.68  Med: 4.70 Max: 14
Current: 2.55
0.68
14
Days Inventory 174.33
SURG's Days Inventory is ranked lower than
66% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. SURG: 174.33 )
Ranked among companies with meaningful Days Inventory only.
SURG' s 10-Year Days Inventory Range
Min: 122.69  Med: 197.57 Max: 332.79
Current: 174.33
122.69
332.79
Days Sales Outstanding 69.79
SURG's Days Sales Outstanding is ranked higher than
51% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. SURG: 69.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
SURG' s 10-Year Days Sales Outstanding Range
Min: 24.57  Med: 64.96 Max: 96.62
Current: 69.79
24.57
96.62

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.81
SURG's Price/Net Current Asset Value is ranked higher than
50% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. SURG: 9.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SURG' s 10-Year Price/Net Current Asset Value Range
Min: 2.67  Med: 6.49 Max: 196
Current: 9.81
2.67
196
Price/Tangible Book 6.03
SURG's Price/Tangible Book is ranked higher than
51% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. SURG: 6.03 )
Ranked among companies with meaningful Price/Tangible Book only.
SURG' s 10-Year Price/Tangible Book Range
Min: 1.84  Med: 5.43 Max: 19.65
Current: 6.03
1.84
19.65
Price/Projected FCF 1.42
SURG's Price/Projected FCF is ranked higher than
85% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. SURG: 1.42 )
Ranked among companies with meaningful Price/Projected FCF only.
SURG' s 10-Year Price/Projected FCF Range
Min: 0.15  Med: 2.55 Max: 23.44
Current: 1.42
0.15
23.44
Price/Median PS Value 1.31
SURG's Price/Median PS Value is ranked higher than
65% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. SURG: 1.31 )
Ranked among companies with meaningful Price/Median PS Value only.
SURG' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 1.49 Max: 7.14
Current: 1.31
0.25
7.14
Price/Graham Number 3.22
SURG's Price/Graham Number is ranked higher than
54% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. SURG: 3.22 )
Ranked among companies with meaningful Price/Graham Number only.
SURG' s 10-Year Price/Graham Number Range
Min: 0.82  Med: 2.68 Max: 11.76
Current: 3.22
0.82
11.76
Earnings Yield (Greenblatt) (%) 3.94
SURG's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. SURG: 3.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SURG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.7  Med: 5.90 Max: 18.4
Current: 3.94
0.7
18.4
Forward Rate of Return (Yacktman) (%) -9.99
SURG's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 4.79 vs. SURG: -9.99 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SURG' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -10.5  Med: 0.30 Max: 1024
Current: -9.99
-10.5
1024

Analyst Estimate

Jul15 Jul16
Revenue(Mil) 74 85
EPS($) 0.16 0.23
EPS without NRI($) 0.16 0.23

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Synergetics USA Inc is a Delaware corporation incorporated on June 2, 2005 in connection with the reverse merger of Synergetics, Inc. and Valley Forge Scientific Corp. The Company is a supplier of precision surgical devices. It develops, manufactures, and markets disposable and durable equipment for use in ophthalmologic, neurosurgical, and other microsurgical applications. The Company's product lines focus upon precision engineered, disposable and reusable devices, procedural kits and the delivery of various energy modalities for the performance of surgery, including: laser energy, ultrasonic energy, radio frequency energy for electrosurgery and lesion generation and visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. It's ophthalmic and vitreoretinal surgical devices and equipment compete against manufacturers of similar products, including those sold by its major competitors, Alcon, Bausch & Lomb, Inc., Dutch Ophthalmic Research Center and Iridex. The Company is subject to macro-economic fluctuations in the United States, the countries of Europe and the economies of other countries throughout the world. Medical device companies are subject to rigorous regulation, including by the FDA and numerous other federal, state and foreign governmental authorities.
» More Articles for SURG

Headlines

Articles On GuruFocus.com
Synergetics USA to Be Acquired by Valeant Pharmaceuticals Sep 02 2015 
Synergetics USA Announces an Early Renewal of the Supply Agreement With Stryker Corporation Jul 22 2015 
Synergetics USA Announces Conference Call to Review First Quarter of Fiscal Year 2015 Results Dec 01 2014 
Synergetics USA Announces Conference Call to Review Fourth Quarter and Fiscal Year 2014 Results Oct 15 2014 
Synergetics USA: A Growth Story Amidst an Aging Population Aug 30 2012 
Synergetics Up 30% after Approval for Eye Surgery Device Jun 28 2012 
Synergetics USA Inc. (SURG) EVP & COO Kurt W Jr Gampp sells 43,000 Shares Mar 15 2011 
Weekly CFO Buys Highlight: CNLG, SIFID, FUL, SURG, TYL Jan 15 2011 
Synergetics USA Inc. (SURG) President and CEO David M Hable sells 17,000 Shares Jan 07 2011 
Weekly CFO Buys Highlight: COIN, INTC, SURG, IBCA, AUMN Oct 24 2010 

More From Other Websites
SYNERGETICS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA,... Sep 04 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergetics USA, Inc. of... Sep 03 2015
Synergetics USA, Inc.: Strong price momentum but will it sustain? Sep 03 2015
Ryan & Maniskas, LLP Announces Investigation of Synergetics USA, Inc. Sep 03 2015
SYNERGETICS USA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Sep 02 2015
SYNERGETICS USA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Sep 02 2015
Harwood Feffer LLP Announces Investigation of Synergetics USA, Inc. Sep 02 2015
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synergetics... Sep 02 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergetics USA, Inc. of... Sep 02 2015
SYNERGETICS USA, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP... Sep 02 2015
Kendall Law Group Investigates Whether Synergetics USA, Inc. Acquisition by Valeant Pharmaceuticals... Sep 02 2015
Synergetics USA (SURG) Stock Soars After Being Acquired by Valeant Sep 02 2015
Valeant Pharmaceuticals (VRX) Stock Climbs on Synergetics Deal Sep 02 2015
SYNERGETICS USA TO BE ACQUIRED BY VALEANT PHARMACEUTICALS Sep 02 2015
Valeant Agrees to Acquire Synergetics Sep 02 2015
SYNERGETICS USA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Launches an Investigation... Sep 02 2015
Valeant to buy ophthalmic surgical device maker Synergetics Sep 02 2015
Synergetics to be acquired by Valeant Pharmaceuticals Sep 02 2015
Valeant Pharmaceuticals To Acquire Synergetics USA Sep 02 2015
Synergetics USA to Be Acquired by Valeant Pharmaceuticals Sep 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK